If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
198
results.
Updated on
12/01/2026 [06:51:00]
Absstract of: WO2025234761A1
The present invention relates to an automated apparatus for producing nanoparticles, and a nanoparticle production method using same. Specifically, the present invention relates to the automated apparatus for producing nanoparticles, comprising: a microfluidic device; a mounting part for fastening the microfluidic device to the automated apparatus; an inlet part that supplies a fluid containing raw materials; a pneumatic pressure control part that provides pressure for fluid movement; and a recovery part that recovers the produced nanoparticles according to the condition thereof.
Absstract of: CN121287655A
本发明公开了一种增强穿透血脑屏障的线粒体纳米囊泡Pep‑1@TMZm@MitoNVs的构建方法，属于靶向胶质母细胞瘤的纳米递药系统的制备领域，修饰联有改性后的替莫唑胺和Pep‑1的纳米颗粒的构建方法，本发明根据纳米载体的特征，开发了一种可以搭载替莫唑胺，并且具有较高的生物利用度、较好的组织相容性、可观的载药率及包封率，较轻的毒副作用的线粒体纳米囊泡，本发明的Pep‑1@TMZm@MitoNVs的线粒体纳米囊泡，基于TMZ的改性和Pep‑1的线粒体纳米囊泡对于能够提高临床一线化疗药物TMZ穿透血脑屏障的能力和肿瘤的靶向性、增强其抗肿瘤活性的有效载体。
Absstract of: CN121294401A
本公开提供了一种新的核酸酶和使用该核酸酶进行基因编辑和核酸检测的方法。在一些实施方案中，本公开提供了该可编程核酸酶是的应用。本公开还提供了包含该可编程核酸酶的组合物、系统和方法。
Absstract of: CN121287657A
本发明属于保健品技术领域，公开了一种涉及柠檬囊泡包埋活性益生菌的制备方法及其应用。本发明公开了一种柠檬囊泡包埋活性益生菌，包括益生菌，以及包覆于益生菌表面的柠檬囊泡，所述柠檬囊泡为柠檬来源的细胞外囊泡。本发明利用柠檬囊泡对活性益生菌进行单细胞的包埋，使其能对抗胃酸和胆汁的降解，提高活性益生菌经过胃在肠道的存活率和定植率，促进活性益生菌在调节肠道微生态的平衡和高效实现活性益生菌的各种功能，同时柠檬囊泡的天然活性成分可以协同降低肠道部位的炎症因子。该柠檬囊泡对活性益生菌提供了一种全新的益生菌递送技术，为未来口服益生菌产业带来新的发展策略。
Absstract of: CN121293117A
本发明提供了一种脂质化合物或其药学上可接受的盐及其制备方法、脂质纳米颗粒和应用，属于生物医药技术领域。该脂质化合物或其药学上可接受的盐，具有式（I）所示的结构式：式（I）；其中，X为C1~C5羟烷基；A、Y、Z分别独立地选自C1~C5亚烷基酯基；R1、R2各自独立地选自C11~C18支链烷基，且R2的碳原子的数量多于R1的碳原子的数量。本发明丰富了脂质化合物及脂质纳米颗粒的种类，对递送核酸药物、预防或治疗疾病具有重要意义。
Absstract of: CN121287656A
本发明提供了一种生物膜融合纳米胶束、载药生物膜融合纳米胶束及其制备方法和应用，属于医药技术领域。本发明中生物膜融合纳米胶束包括弹性蛋白样多肽纳米胶束、包覆在弹性蛋白样多肽纳米胶束表面的癌细胞膜、位于弹性蛋白样多肽纳米胶束与癌细胞膜之间的L‑精氨酸、以及位于癌细胞膜的磷脂双分子层之间的脂溶性光敏剂。本发明中生物膜融合纳米胶束能够绕过传统的内吞途径，有利于提高治疗效果；利用弹性蛋白样多肽纳米胶束的亲疏水结构便于实现对脂溶性化疗药物（如雷帕霉素或阿霉素）的包封，利用其疏水作用可以将脂溶性光敏剂（如光敏剂IR780或光敏剂ICG）嵌入癌细胞膜的磷脂双分子层中，可实现癌症协同化疗、光动力治疗和气体治疗。
Absstract of: CN121293307A
本发明涉及一种肿瘤来源IgG抗体偶联的人重组铁蛋白装载CpG的纳米肿瘤疫苗。本发明的纳米肿瘤疫苗包括人重组铁蛋白核壳结构，表面偶联肿瘤来源IgG抗体，并在其核心携载CpG。本发明还涉及该纳米肿瘤疫苗在治疗黑色素瘤中的应用。
Absstract of: CN121287662A
本发明涉及一种药物递送系统，具体涉及一种白藜芦醇‑介孔硅共价接枝纳米药物递送系统、制备方法及其应用，所述系统包括介孔二氧化硅纳米粒子载体、白藜芦醇活性成分以及连接白藜芦醇与介孔二氧化硅纳米粒子的响应性链接基团；所述白藜芦醇通过其4'‑位酚羟基选择性连接于所述响应性链接基团上；所述响应性链接基团包括酸敏感的缩醛键和酶敏感的酯键组合结构；所述介孔二氧化硅纳米粒子表面修饰有聚乙二醇和叶酸靶向基团，保留了其3位和5位羟基的抗氧化活性，既实现了稳定共价连接，又保持了药物分子的活性部分。
Absstract of: CN121287887A
本申请属于生物医药技术领域，具体公开了一种胞内递送尿酸酶的茶多酚自聚纳米粒及其制备方法与应用，包括茶多酚自聚化合物和尿酸酶，茶多酚自聚化合物由表没食子儿茶素没食子酸酯在Mn2+的催化下初步自聚形成，多酚自聚化合物再与尿酸酶混合，对尿酸酶进行包载得到茶多酚自聚纳米粒。该茶多酚自聚纳米粒具有基于EGCG载体（TPNs）的尿酸酶联合递送、协同治疗的功能，可以有效维持尿酸酶的三级结构完整性，确保其活性；同时还能保护尿酸酶免受蛋白酶的破坏，增强了尿酸酶的稳定性。通过尿酸酶和TPNs在胞内的协同作用，对胞内尿酸盐结晶以及炎症反应实现“标本兼治”，为痛风或者高尿酸血症提供了更优的方案选择。
Absstract of: US2025032620A1
Formulated and/or co-formulated liposomes, lipid nanoparticle (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other diseases by utilizing a targeted drug delivery vehicle.
Absstract of: CN121294536A
本发明公开了一种以ITR末端闭合的线性非病毒DNA载体及其制备方法和应用。所述线性非病毒DNA载体包括以下元件：不对称反向末端重复ITR序列和表达盒；所述不对称反向末端重复ITR序列包括第一ITR序列和第二ITR序列，所述第一ITR序列和第二ITR序列分别位于表达盒序列的两端以使表达盒为闭合的，所述表达盒包括顺式调节元件；所述第一ITR序列和第二ITR序列和/或结构相同或不同。所述线性非病毒DNA载体合成简单、免疫原性低、能够长期表达，可用于体内体外进行稳定可靠的目的基因的表达，为基因治疗提供了更好的表达载体。
Absstract of: US2025296980A1
Disclosed herein are extracellular vesicles comprising an immunomodulating component. Also provided are methods for producing the extracellular vesicles and methods for using the extracellular vesicles for treating cancer, GvHD, and autoimmune diseases.
Absstract of: CN121287652A
本发明属于纳米光动力材料以及生物技术领域，公开了一种PEG‑PLGA封装叶酸靶向偶联硅酞菁纳米光敏剂及其制备方法和应用。本发明利用开环聚合制备PEG‑PLGA低聚物；水解二氯硅酞菁，制备二羟基硅酞菁；二羟基硅酞菁和(3‑氨基丙基)二甲基乙氧基硅烷缩合反应，制备氨基化硅酞菁；在二苯基硅烷催化下，氨基化硅酞菁偶联叶酸，制备具有靶向选择性的光敏剂；在超声分散下，水包油乳化，制备PEG‑PLGA@SiPc‑Fa纳米光敏剂。本发明制备的PEG‑PLGA@SiPc‑Fa纳米光敏剂，利用680nm红光光照，应用于光动力治疗鳞状细胞癌，具有光动力治疗效应，对小鼠实体瘤的生长具有抑制效果。
Absstract of: CN121287654A
本发明涉及药物制剂技术领域，提供了一种双壳层JAK抑制剂纳米粒及其制备方法和靶向递送滴眼液。本发明提供的双壳层JAK抑制剂纳米粒包括核芯、内壳层和外壳层，核芯包括纳米结构脂质载体和JAK抑制剂；内壳层为阳离子聚合物，外壳层为透明质酸。本发明通过“正电荷内壳层+负电荷外壳层”的设计，不仅实现了粘膜黏附和主动靶向的双重功能，而且最终纳米粒表面呈负电性，减少了由阳离子聚合物直接暴露可能引起的细胞毒性，避免了与泪液中带负电的蛋白质发生非特异性聚集，提高了制剂的稳定性。本发明提供的滴眼液能够显著提高JAK抑制剂在眼表的驻留时间、增强角膜渗透性、并能主动靶向至眼部炎症细胞，具有广阔的应用前景。
Absstract of: CN121287608A
本发明公开一种核酸药物递送系统及其制备方法和用途。所述核酸药物递送系统包括光交联水凝胶和阳离子脂质纳米颗粒，所述阳离子脂质纳米颗粒负载于所述光交联水凝胶中，所述阳离子脂质纳米颗粒包封有抑制REST基因表达的siRNA，所述siRNA的核苷酸序列包含SEQ ID No.1和SEQ ID No.2所示序列。本发明的核酸药物递送系统在脊髓损伤局部组织植入后，缓释包封siRNA的阳离子脂质纳米颗粒，实现对REST基因的持续沉默促进轴突再生，同时光交联水凝胶发挥ROS清除作用，此外，还能促进巨噬细胞M2极化调控免疫微环境，从而在分子和细胞水平上协同促进神经修复，实现“免疫调控‑轴突再生”双轨并行，因此在治疗脊髓损伤中具有广阔的应用前景。
Absstract of: CN121287660A
本发明公开了一种载铁蛋白偶联黑色素纳米颗粒及其制备方法与应用，涉及生物医学技术领域，载铁蛋白偶联黑色素纳米颗粒AFn‑MNP包括载铁蛋白和黑色素纳米颗粒，两者共价连接形成核壳结构，具备优异的铁离子螯合能力和抗氧化活性。AFn‑MNP能够有效清除活性氧（ROS），抑制光感受器细胞的铁死亡，逆转视网膜氧化损伤。在干性年龄相关性黄斑变性（dAMD）模型中，单次玻璃体内注射AFn‑MNP显著改善视觉功能，保护视网膜结构完整性。本发明为治疗dAMD及其他视网膜变性疾病提供了新型纳米治疗策略。
Absstract of: WO2024211865A2
The current disclosure relates to lipid-based compositions and methods of administering therapeutic agents relating thereto. In particular, the disclosure relates to lipid-like substituted aryl and/or heteroaryl compounds, substituted piperazines, and/or other aryl and/or heteroaryl lipid compounds as LNP delivery materials that may be incorporated into lipid-based compositions to increase efficiency of delivery of a therapeutic agent(s) to tissues of a subject.
Absstract of: CN121287661A
本发明属于生物医药技术领域，具体涉及仿生杂化膜涂层载黄芩素的原花青素纳米制剂及其制备方法与应用。该原花青素纳米制剂由原花青素，黄芩素，红细胞膜，小胶质细胞膜、RVG靶向肽和MG1靶向肽制成；黄芩素包载于原花青素自组装形成的纳米粒PC@BAI中，仿生杂化膜作为外层包覆于纳米粒PC@BAI的表面，得到纳米材料M@PC@BAI，RVG靶向肽和MG1靶向肽修饰于纳米材料M@PC@BAI的表面，得到纳米制剂RVG/MG1‑M@PC@BAI。本发明通过仿生杂化膜涂层结合天然细胞膜的生物学功能和合成脂质的稳定性，赋予纳米制剂出色的长效血液循环能力及对脑部病变区域的主动靶向能力，显著提高药物在脑内的富集。
Absstract of: CN121287885A
本发明公开了一种HGF mRNA脂质纳米颗粒（LNP）及其应用。本申请构建了一种基于脂质纳米颗粒（LNP）的可靶向肝脏的HGF mRNA递送系统，实现了在自身免疫病灶部位可控地表达HGF，从而抑制异常炎症和免疫反应、促进组织修复，同时最大限度降低全身毒性与长期安全风险。
Absstract of: CN121287658A
本发明公开了一种用于克服肿瘤溶酶体耐药隔离的肽基药物递送系统及其制备方法与应用。所述肽基药物递送系统由功能化多肽及肝素经多级自组装形成纳米颗粒。该纳米颗粒在循环阶段保持稳定的大粒径与负电性；在肿瘤区域给药后，响应肿瘤微环境中高表达的乙酰肝素酶，解离为具有高组织穿透能力的小粒径正电性颗粒；最终在溶酶体酸性环境及组织蛋白酶B的协同激活下，多肽发生构象转变，自组装形成β‑折叠纳米纤维，通过机械作用破坏溶酶体膜完整性，从而促使被隔离的药物从溶酶体中逃逸，有效逆转溶酶体介导的耐药效应。本发明适用于包括胶质瘤放射治疗与经导管动脉化疗栓塞在内的多种治疗策略，用于解决实体肿瘤中的溶酶体药物隔离问题。
Absstract of: CN121293347A
本发明公开了一种抗DAT抗体，经由一片段基因转录及转译后所形成，其中该片段基因包含SEQ ID No:2。本发明所提供的抗DAT抗体可制成具备穿越血脑屏障的组合物，并可针对多巴胺神经细胞达到专一性的结合，以及达到降低多巴胺神经细胞退化或病变的纹状体(striatum)脑区中蛋白突触核蛋白堆积并产生延缓帕金森氏症病程的优异效用。
Absstract of: CN121287659A
本发明公开了一种双特异性抗体纳米盘及其制备方法和应用。本发明提供的制备方法包括下述步骤：将CD3抗体基因与PD‑L1抗体基因经疏水跨膜区连接后克隆至pCDH载体，包装慢病毒感染293T细胞，经嘌呤霉素筛选获得稳定表达CD3×PD‑L1双特异性抗体的293T细胞；超声破碎并梯度离心收集CD3×PD‑L1双特异性抗体细胞膜囊泡；按1﹕1﹕5质量比将22A多肽、所述囊泡与DMPC混合，3‑5℃低速旋转混匀11‑13小时，得到双特异性抗体纳米盘。本方案能够提高双特异性抗体的肿瘤靶向效果，增强抗肿瘤作用。
Absstract of: WO2026011085A1
This disclosure provides nanoparticle compositions, and use thereof for isolating and measuring proteins, protein degrader action, and cells. The disclosed nanoparticles can be identified by barcodes that reveal the identity of and post translational modifications to the bound protein using image processing techniques described herein.
Absstract of: WO2026008881A1
The present invention is in the field of medicine. More specifically, the present invention relates to extracellular vesicles, namely lipid nanoparticles that are conjugated to a biomolecule, namely an antibody or a nanobody, using a click reaction. Such extracellular vesicles can be applied for more effective treatment of diseases, in particular in vivo CAR T therapy, cardiac fibrosis and lysosomal storage diseases (LSD).
Absstract of: WO2026010842A1
The present invention relates to compositions for inducing an immune response against a tumor antigen in a subject, the composition comprising at least one mRNA encoding at least one tumor antigen selected from the group consisting of hTERT, mTERT, and KRASG12D, encapsulated in a lipid nanoparticle.
Absstract of: WO2026010674A1
The present invention discloses a formulation with improved skin permeability. Particularly, the invention is related to a formulation in the form of nanoemulsion comprising at least one lubricant, saponin, oil component, surfactant and at least one pharmaceutical or nutraceutical active ingredient with improved skin permeability.
Absstract of: WO2026010484A1
The present invention relates to multi-layer nanoparticles for nucleic acid delivery, a method for preparing same, a nucleic acid delivery composition comprising same, an antibacterial composition, and a pharmaceutical composition for preventing or treating infectious diseases. The multi-layer nanoparticles for nucleic acid delivery comprise: gold nanoparticles; a polyethyleneimine modified on the surface of the gold nanoparticles; and chitosan applied on the gold nanoparticles modified with the polyethyleneimine. According to the present invention, the introduction of nucleic acids (e.g., ASOs) into target bacterial cells is maximized, and highly efficiently loaded nucleic acids can be effectively delivered into bacteria to maximize the effect of inhibiting target nucleic acids, and thus the present invention can be useful as an antibacterial agent and a gene therapeutic agent.
Absstract of: WO2026010421A1
The present invention relates to a ferritin-protein complex capable of dual targeting and a use thereof. The dual-target ferritin-protein complex of the present invention can selectively deliver a drug only to tumor tissues and cancer cells, thereby increasing the efficacy of the drug.
Absstract of: WO2026010380A1
The present invention relates to a pharmaceutical composition containing lipid nanoparticles that can be used as a drug delivery system (DDS) through blood by loading an mRNA form of a useful anticancer agent or immunomodulator. The lipid nanoparticles (so-called GrAb-LNP) of the present invention do not induce hepatotoxicity in vivo and inhibit the aggregation reaction of proteins present in blood, thereby being able to be effective DDS. That is, the GrAb-LNP of the present invention can act in a target-specific manner on a target tumor or target immune cells by loading mRNA encoding a protein used as an anticancer agent or immunomodulator, thereby allowing for the treatment of cancer or the modulation of immune cells while minimizing damage to normal cells.
Absstract of: WO2026010379A1
The present invention relates to a pharmaceutical composition containing HER2-binding lipid nanoparticles loaded with mRNA encoding p53 protein. The so-called "p53 mRNA-loaded HER-binding lipid nanoparticles" developed in the present invention were verified to deliver p53 mRNA, a tumor inhibitor, which targets highly expressed HER2 in a "human epidermal growth factor receptor 2 (HER2)-positive cancer cell" model, and thus can induce cancer cell death without systemic toxicity.
Absstract of: WO2026009946A1
The purpose of the present invention is to provide: lipid nanoparticles useful as a nucleic acid delivery carrier; and a novel pH-sensitive cationic lipid for producing the lipid nanoparticles. The problem is solved by: a pH-sensitive cationic lipid comprising an asymmetric hydrocarbon chain; and lipid nanoparticles comprising the pH-sensitive cationic lipid as a constituent lipid.
Absstract of: WO2026008008A1
Disclosed herein are a lipid compound based on a biodegradable isocyanide or a biodegradable carboxylic acid terminal group, a preparation method therefor, and a use thereof in the preparation of a lipid compound for gene delivery. Further disclosed herein are a lipid compound for gene delivery, a preparation method therefor, and a use thereof in gene delivery. Further disclosed herein are a liposome and a lipid nanoparticle that comprise the lipid compound for gene delivery, and a gene delivery composition comprising the lipid compound, the liposome, or the lipid nanoparticle. The lipid compound for gene delivery, the liposome, the lipid nanoparticle, and the gene delivery composition herein enable more selective and efficient delivery and release of biomolecules, such as nucleic acids, in immune tissues and organs in vivo.
Absstract of: WO2026007911A1
Disclosed in the present invention are a novel carrier having the functions of inducing ferroptosis and delivering a nucleic acid drug, and use thereof in tumor treatment. The artesunate-protamine conjugate carrier of the present invention conjugates artesunate with protamine by means of an amide bond. The artesunate-protamine conjugate carrier prepared by the present invention has the characteristics of simple components and small toxic and side effects, and can induce ferroptosis of tumor cells. Moreover, said carrier has the function of delivering nucleic acids, and can be used for research in the anti-tumor field.
Absstract of: WO2026007662A1
The present invention relates to a material for local drug delivery and use thereof. Specifically provided is a nanoparticle composition. The nanoparticle composition comprises a cationic lipid, a PEG lipid, and a structural lipid, wherein the lipid component of the PEG lipid is 1.0-5.5 mol%, or a range between any two of the described values. The nanoparticle composition of the present invention is delivered only at the site of administration.
Absstract of: WO2026007297A1
A preparation method for a multifunctional biomimetic delivery platform efficiently crossing mucosal barriers and inducing mucosal immune enhancement and use thereof. The present invention relates to the technical field of biopharmaceuticals. On the basis of a biodegradable PLGA copolymer and a mixed lipid component, mucosal delivery carrier particles capable of simultaneously loading multiple antigens and immunostimulatory components are prepared by means of a double emulsion method, a rotary evaporation coating method, and an ultrasonic method. The PLGA nanoparticles are loading cores. The outer mixed lipid coating can fulfil the functions of mucus penetration, cell uptake, and thus immune activation.
Absstract of: WO2026007226A1
A nanoparticle loaded with an oral protein drug for the treatment of diabetes and a carrier. Raw materials of said nanoparticle comprise: a lipid molecule-modified zwitterionic polymer, a cationic lipid, a phospholipid, and cholesterol. The lipid molecule-modified zwitterionic polymer is composed of a lipid molecule and a polymer, wherein the lipid molecule is distearoyl phosphoethanolamine or dimyristoylglycerol, and the polymer is a poly(carboxybetaine) polymer, a poly(phosphobetaine) polymer, a poly(sulfobetaine) polymer, or poly-2-(N-oxide-N,N-diethylamino)ethyl methacrylate. Said nanoparticle significantly improves the oral bioavailability of the protein drug.
Absstract of: WO2026006906A1
A lipid nanoparticle delivery system; it has a cargo molecule; and a lipid nanoparticle encapsulating the cargo molecule, the lipid nanoparticle comprising ionizable lipids; helper lipids; sterol; and acid-containing lipids that are crosslinked; and methods of use thereof.
Absstract of: WO2026007157A1
The present invention relates to the synthesis of a peptide-based ionizable lipid and the use thereof, and specifically relates to an amino acid molecular building block with an alkylated side-chain primary amino group, a peptide-based ionizable lipid (PIL) formed therefrom, a method for synthesizing PIL, and a PIL library containing a plurality of PILs. The present invention further relates to a lipid nanoparticle (LNP) containing PIL, in particular a PIL-mediated organ-targeted LNP (PILOT LNP), a pharmaceutical composition containing same, and a targeted delivery method for administering the LNP or the pharmaceutical composition, or a method for preventing or treating a disease.
Absstract of: AU2024303855A1
The present disclosure provides a therapeutic nanodisk, the therapeutic nanodisk comprising: a lipid-binding polypeptide; a lipid bilayer and a therapeutic agent, wherein the therapeutic agent may be of use for treating, preventing a central nervous system disease, disorder, trauma or injury; or as a diagnostic agent for diagnosing a central nervous system disease, disorder, trauma or injury. The lipid bilayer may be 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and the therapeutic agent may be a nucleic acid polymer. Further provided are methods for administration of the therapeutic nanodisk to treat, prevent or diagnose the central nervous system disease, disorder, trauma or injury and uses of such therapeutic nanodisks.
Absstract of: AU2024289812A1
The present invention relates to a composition comprising a solid carrier, a protein disaccharidase or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein disaccharidase or a fragment thereof by embedding the protein disaccharidase or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group. The present invention also relates to methods of producing said composition.
Absstract of: US2024423914A1
Compounds are provided having the following Formula (I):or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein G1, R1, R2, R3, L1, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Absstract of: US2025025427A1
Compounds are provided having the following Formula (I):or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein G1, G2, R1, R2, R3, L1a, L1b, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Absstract of: WO2025019903A1
The present invention relates to RNA-containing vaccine compositions for inducing an immune response to Porphyromonas gulae in a subject, and uses thereof.
Absstract of: AU2024289192A1
The present invention relates to a method of producing a composition, the composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group. The present invention also relates to the composition obtainable by the method.
Absstract of: AU2024285136A1
Compositions are provided that include a lipid nanoparticle (LNP);a self-replicating RNA encoding a gene of interest loaded within the LNP; and an inhibitory nucleic acid, such as a small interfering RNA (siRNA) targeting IFN-α/β receptor l(Ifharl) gene loaded within the LNP, and use of the compositions for generating an immune response.
Absstract of: AU2024280598A1
A siRNA molecule for inhibiting expression of plasminogen activator inhibitor-1 (PAI-1) is disclosed and may have a sense strand and an antisense strand. The sense strand may have at least 80% sequence identity to any one of SEQ ID NOs: 3, 5, 7, and 9. In some embodiments, the antisense strand may have at least 80% sequence identity to any one of SEQ ID NOs: 4, 6, 8, and 10. The sense strand and/or the antisense strand may comprise one or more modified nucleotides. The sense strand and/or the antisense strand may comprise of a ligand. A lipid nanoparticle comprising the siRNA molecule is also disclosed. Methods of using the siRNA molecule or the lipid nanoparticle comprising the siRNA molecule to treat a subject who suffers from at least one PAI-1-associated condition, disease or disorder are also disclosed.
Absstract of: AU2024290815A1
The present invention relates to a composition comprising a solid carrier, a lipase or a fragment thereof immobilized on the surface of the solid carrier, an agent which interacts with the lid domain of the lipase or a fragment thereof, and a protective layer to protect the lipase or the fragment thereof by embedding the lipase or the fragment thereof, wherein the lipase or a fragment thereof is in the open conformation. The present invention also relates to methods of producing said composition.
Absstract of: AU2024272060A1
The present disclosure describes improved LNP-based nucleobase editing systems and therapeutics for use in treating hemoglobinopathies, including sickle cell disease and beta-thalassemia. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based nucleobase editing systems and therapeutics to red blood cell progenitor cells, enabling treatment of hemoglobinopathies, in vivo.
Absstract of: AU2024275548A1
The disclosure provides ionizable lipids and lipid nanoparticle (LNP) compositions comprising ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.
Absstract of: AU2024272799A1
The present invention provides a method of producing extracellular vesicles (EVs) comprising incubating or culturing EV producing cells in media. The present invention also provides a population of EVs and compositions comprising the vesicles and methods and uses thereof.
Absstract of: AU2024272694A1
The present disclosure relates to microRNAs (miRs) and extracellular vesicles comprising same and therapeutic uses thereof, for example, in modulating angiogenesis.
Absstract of: WO2026009174A1
The present application discloses formulations comprising polyphenol- loaded phospholipid nanomicelles. The described phospholipid nanomicelles are loaded with resveratrol and/or rutin, which are particularly suitable for the delivery of these polyphenols. The formulations herein described is also suitable for skin diseases or conditions which can be prevented or treated with the administration of resveratrol and/or rutin.
Absstract of: WO2026010906A1
Provided herein are compositions, methods, and particles that include a peptide that targets placental chondroitin sulfate A (placental CSA), wherein the amino acid sequence of the polypeptide is as set forth in SEQ ID NO: 1 (EDVKDINFDTKEKFLAGLIVSFHEGKC).
Absstract of: MX2025012226A
Disclosed herein is a polysialic acid (PSA)-polymer conjugate compound represented by the structural formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200, nanoparticles comprising same, and methods of treating ophthalmic diseases using same.
Absstract of: AU2024229078A1
The present invention relates to nanocomplexes (NCs) comprising a polysaccharide nanoparticle (NP) and a hormone selected from insulin, glucagon, or glucagon-like protein-1, and uses thereof for reducing the blood glucose level, in particular, for the treatment of diabetes.
Absstract of: MX2025011256A
The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.
Absstract of: MX2025010922A
Provided is an anti-Claudin18.2 nanobody or a binding fragment thereof. The antibody has good specificity, and immune effector cells targeting Claudin18.2 which are prepared from the antibody show a good therapeutic effect in treating or ameliorating diseases having positive expression of Claudin18.2.
Absstract of: GB2642389A
This disclosure provides the use of nanoparticles of self-assembled acidic molecular clusters (NP-AMCs) of ammonium salts to lower the pH of skin and underlying tissue of a human or other mammal as a means of stimulating the localized immune response to a wound.
Absstract of: EP4674856A2
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
Absstract of: EP4675006A2
A method of preparing a pharmaceutical composition is provided. The method includes the deposition of a metal oxide layer(s) followed byapplying a polymer layer(s). This produces a pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials and one more polymer materials.
Absstract of: EP4674857A2
The present disclosure relates to spheroidal organosiloxane submicron/nanoparticle comprising a network consisting of organosiloxane, and a process to make them.
Absstract of: EP4674412A1
The present invention relates to a microfluidic device for preparing lipid nanoparticles capable of delivering nucleic acids, and a method for preparing lipid nanoparticles using the same. Using the microfluidic device, lipid nanoparticles having a desired size can be prepared by adjusting the molar ratio of compositions and the Reynolds number.
Absstract of: CN120641393A
The present invention provides, in part, a diester and amide cationic lipid compound of formula (I): # imgabs0 # or a pharmaceutically acceptable salt thereof; a diester and amide cationic lipid compound of formula (II): # imgabs 1 # or a pharmaceutically acceptable salt thereof; a diester and amide cationic lipid compound of formula (III): # imgabs2 # (III), or a pharmaceutically acceptable salt thereof; and a diester and amide cationic lipid compound of formula (IV): # imgabs3 # or a pharmaceutically acceptable salt thereof. The compounds provided herein can be used to deliver and express mRNA and encoded proteins, for example, as components of liposomal delivery vehicles, and thus can be used to treat various diseases, disorders, and conditions, such as those associated with the lack of one or more proteins.
Absstract of: WO2024130086A1
Disclosed herein are lipid compounds and compositions comprising lipid compounds and methods of making and use thereof. The present disclosure also relates to methods for delivering an agent into a cell by introducing to the cell a therapeutically effective amount of the compositions, the lipid nanoparticles, the pharmaceutically acceptable compositions, or the hydrogel matrices disclosed herein. Also disclosed herein are methods for promoting wound repair in a subject by administering to the subject a therapeutically effective amount of the compositions, the lipid nanoparticles, the pharmaceutically acceptable compositions, or the hydrogel matrices disclosed herein.
Absstract of: MX2025009920A
The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use.
Absstract of: MX2025014185A
Provided is a polymer comprising a structure of Formula (1): (1) and a method of preparing said polymer. Also provided is a composition comprising the polymer and a nucleic acid and/or polypeptide, and a method of delivering a nucleic acid and/or polypeptide to a cell.
Absstract of: MX2025014047A
This application disclose a polynucleic acid molecule conjugate comprising an antibody or binding fragment thereof conjugated to a polynucleic acid molecule that hybridizes to a target sequence of an atrogene; wherein the polynucleic acid molecule comprises at least one 2' modified nucleotide, at least one modified intemucleotide linkage, or at least one inverted abasic moiety; and wherein the polynucleic acid molecule conjugate mediates RNA interference against the atrogene, thereby treating muscle atrophy or myotonic dystrophy in a subject. In a certain embodiment, atrogene comprises atrogin-1 gene (FBXO32), MuRF1 gene (TRIA63), FOXO1, FOXO3, or MSTN.
Absstract of: CN120813339A
There is provided a compound represented by general formula (1) or an ionized form thereof for use in the preparation of lipid nanoparticles encapsulating therapeutic, prophylactic and/or biological agents: wherein NR1R2 is a group ionizable at pH from 3 to physiological pH; a comprises a linear aliphatic hydrocarbon, a branched aliphatic hydrocarbon and/or a cyclic hydrocarbon, optionally comprising one or more groups selected from the group consisting of-OH,-NR-,-O-,-O-CxH2x-O-, where x > = 1; and wherein R is H, an optionally substituted alkyl group, an optionally substituted alkenyl group, or an optionally substituted alkynyl group; r3, R4, R5, R6 and R7 are each independently H, an optionally substituted alkyl group, an optionally substituted alkenyl group or an optionally substituted alkynyl group; and R8 and R9 are each independently a hydrophobic group.
Absstract of: EP4674431A1
The present disclosure is a lipid nanoparticle including a composition including a protein selected from an antibody and an antibody fragment, a polymer, and a lipid, in which the polymer and the protein have opposite charges at a predetermined pH. The lipid nanoparticle preferably has a protein encapsulated therein. In addition, when the particle diameter of the lipid nanoparticles is measured, the peak top of the particle diameter distribution is preferably at 80 nm to 120 nm.
Absstract of: MX2025013817A
The present disclosure relates to a process for the preparation of tolerizing immune modifying nanoparticles encapsulating antigens associated with primary biliary cholangitis (PBC), compositions comprising the particles and use thereof for the treatment of PBC.
Absstract of: CN121265555A
本发明属于硒纳米颗粒复合材料技术领域，具体涉及一种巴利森苷修饰的硒纳米颗粒及其制备方法和应用。本发明提供的巴利森苷修饰的硒纳米颗粒，具有核壳结构，包括硒纳米颗粒和包覆在硒纳米颗粒表面的巴利森苷。所述巴利森苷修饰的硒纳米颗粒中巴利森苷分子对葡萄糖转运蛋白‑1具有亲和力，表现出良好的靶向潜力，并具有良好的抗氧化效果。超小剂量的巴利森苷修饰的硒纳米颗粒可通过抗氧化活性缓解过氧化氢造成的不同程度细胞损伤，表现出良好的肝保护效果，可作为一种高效保肝护肝体系。
Absstract of: CN120603949A
The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of treating cancer using the inhibitory nucleic acids.
Absstract of: CN121271804A
本发明涉及一种条件激活型免疫细胞及其组合物和应用。具体地，本发明提供一种偶联纳米颗粒的免疫细胞，免疫细胞表达嵌合抗原受体，所述免疫细胞通过连接子与纳米颗粒偶联，其中，所述连接子包含第一肽段，所述第一肽段包含一个或多个配体诱导型蛋白酶水解裂解位点。本发明提供一种定点“开关型”表达嵌合抗原受体的免疫细胞，能够实现对免疫细胞的精准调控，可有效降低靶向脱瘤毒性，进而降低毒副作用，极大地提高了安全性。
Absstract of: CN121265552A
本发明属于医药技术领域，公开一种负载银纳米粒的脂质体纳米制剂及其制备和应用。本发明采用薄膜分散法制得包载银纳米粒的纳米颗粒。本发明的仿生纳米药物有助于解决抗菌药物银纳米粒细菌摄取效率低的问题，提高药物杀灭瘤内菌的能力，进而提高抗肿瘤效果。制备工艺简单、成本低、稳定性好、可重复性高。
Absstract of: AU2024255212A1
A nanoparticle is described, which comprises a plurality of therapeutic molecules arranged in the form of a spherical micelle, suitable for the localized delivery and release of mycophenolic acid, and therefore effective in the treatment of autoimmune diseases, fibrotic diseases and/or organ rejection diseases, in particular of the lungs. A pharmaceutical composition comprising the nanoparticle in a pharmaceutically acceptable vehicle, and a method for manufacturing said nanoparticle are also described.
Absstract of: CN121265813A
本发明属于生物医药技术领域，具体涉及一种pH响应性纳米药物递送系统及其制备方法与应用。所述pH响应性纳米药物递送系统由羧基化修饰的介孔硅基纳米载体、羧基活化剂和壳聚糖制得；该药物递送系统的制备方法包括提供介孔硅基载体、进行羧基化修饰和壳聚糖接枝三个步骤。本发明通过壳聚糖层实现对肿瘤酸性微环境的响应、以及靶向释放药物，可提高药物的疗效并降低毒副作用，该药物递送系统制备工艺简单、成本低廉、生物相容性好且载药量高。
Absstract of: CN121270966A
本发明公开了一种用于mRNA递送的二硒键交联聚乙烯亚胺载体及其制备方法和用途，所述载体的制备是以合成的二硒‑1,6‑己二醇二丙烯酸酯单体(DSeDA)作为二硒交联剂，与分子量为0.6kDa/1.8kDa的分支PEI通过胺‑丙烯酸酯的Michael加成反应制备二硒交联的聚合物材料，且对未交联的伯胺进行疏水/亲水链的修饰，所述亲/疏水链为化合物CH2COO‑R，取代基R为C8‑C12直链烷基或聚乙二醇的6‑12寡聚体中的一种或几种。本发明载体结构中，交联剂引入可生物降解的二丙烯酸酯键和二硒键，在保持转染效率的同时最大限度地降低毒性。由于二硒键可同时对氧化和还原环境作出灵敏的响应，含二硒键聚合物分子可以成为一类新型的mRNA载体材料，在提高胞内mRNA释放和翻译方面可发挥促进作用。
Absstract of: CN121265559A
本发明提供了一种负载核苷类似物的递送系统及其制备方法和应用，涉及医药技术领域。本发明中通过膜工程改造首次采用血小板膜与MSC细胞外泌体杂化获得的包裹材料负载吉西他滨，获得了高包封率、高载药量的吉西他滨递送系统，并且该系统具有优异的稳定性；该负载吉西他滨的血小板膜药物递送系统能够有效提高吉西他滨的胰腺癌治疗效果，为胰腺癌治疗提供了一种新的功能性药物形式。
Absstract of: CN121265557A
本发明属于生物医药领域，具体涉及一种用于局部给药的脂质纳米颗粒、其制备方法及其在制备抗疤痕药物上的应用。本发明的脂质纳米颗粒，包含脂质载体以及由所述脂质载体所包裹的核酸，所述脂质载体包含以下成分：可电离脂质、永久性阳离子脂质、聚乙二醇化脂质、辅助磷脂和甾醇类化合物；所述可电离脂质、永久性阳离子脂质、聚乙二醇化脂质、辅助磷脂和甾醇类化合物的摩尔比为：25‑45：5‑25：1‑2：5‑15：35‑40。本发明针对现有技术存在的脂质纳米颗粒给药单一性的问题，将脂质纳米颗粒通过比例调控，设计成外用涂抹局部给药，提高靶向性、可给药浓度。避免全身血液循环，降低毒副作用、脱靶性。从而达到“增效”与“减毒”的双重目的。
Absstract of: CN120242044A
The invention belongs to the technical field of biological medicine, and relates to a targeting drug delivery carrier and a preparation method thereof. The invention provides a targeting drug delivery carrier. The targeting drug delivery carrier comprises a drug carrier and targeting polypeptide, the drug carrier is a virus carrier, and the nucleotide of the targeting polypeptide is operably connected with the nucleotide of the capsid protein of the virus carrier; or the drug carrier is a non-viral carrier, the targeting polypeptide is connected with the non-viral carrier in a surface modification mode, and the amino acid sequence of the targeting polypeptide is shown as any one of SEQ ID NO: 8-12 and SEQ ID NO: 14. The efficient drug delivery carrier is designed and prepared by utilizing targeting polypeptide for specifically recognizing biomolecules, cells, tissues or organs.
Absstract of: CN121270779A
本发明公开了两亲性嵌段聚合物、载药纳米颗粒粉末、载药水凝胶及制备方法和应用，涉及骨损伤修复药物技术领域。两亲性嵌段聚合物的制备方法为：4‑二甲氨基苯酚与2‑溴异丁烯酰溴混合反应，得到引发剂P1；N‑叔丁羰基乙醇胺与甲基丙烯酰氯混合反应，得到单体Boc‑AEMA；1‑甲基‑2‑羟甲基咪唑与甲基丙烯酰氯混合反应，得到单体MPID；引发剂P1与单体Boc‑AEMA、单体MPID混合反应，得到聚合物BMP1；聚合物BMP1与三氟乙酸混合反应，得到两亲性嵌段聚合物BMP2。本发明通过设计含阳离子咪唑基团MPID与疏水脱保护胺基Boc‑AEMA的两亲性嵌段聚合物BMP2，突破传统凝胶需添加化学交联剂的局限，通过静电自交联触发原位凝胶化，规避外源交联剂导致的细胞毒性，且凝胶强度可通过聚合物浓度精准调控。
Absstract of: CN121265551A
本发明涉及局部递送药物的材料及其应用。具体提供一种纳米颗粒组合物，所述纳米颗粒组合物包括阳离子脂质、PEG脂质和结构脂质；其中，PEG脂质的脂质组分为1.0‑5.5摩尔％，或上述任意两个数值之间的范围。本发明纳米颗粒组合物仅在施用部位递送。
Absstract of: CN121265756A
本发明涉及一种可屏蔽NETs的神经营养因子纳米递送系统及其应用，属于生物医药技术领域。本发明通过ATP对荷正电的BDNF进行可逆修饰得到荷负电的A‑BDNF；通过LPS处理小胶质细胞得到高表达聚唾液酸的小胶质细胞膜，使用PBM包被A‑BDNF得到A‑BDNF@PBM NPs。本发明的A‑BDNF@PBM NPs可有效富集于受损脊髓部位，并通过PBM表面高表达的聚唾液酸与NETs结合，触发PBM脱落，使位于PBM胞质小叶的PS暴露在NETs表面，PS充当“吃我”信号，使吞噬细胞通过胞葬作用清除NETs，引发神经保护性免疫反应。同时，释放的A‑BDNF在微酸性环境下恢复为BDNF，促进神经再生。
Absstract of: CN121265556A
本发明提供了一种脂质纳米颗粒的制备及其在膀胱灌注药物中的应用，属于生物医药技术领域。本发明脂质纳米颗粒由离子型脂质、胆固醇、两亲性脂质和DOPE‑LA组成；所述离子型脂质为阳离子脂质或可电离脂质，该脂质纳米颗粒（LANP）表面具有二硫戊环结构，能够与细胞表面的巯基发生巯基‑二巯基交换反应，将LANP以化学键的形式黏附在膀胱内壁的黏膜上，以抵抗尿液外排导致的药物有效浓度降低。
Absstract of: AU2024207086A1
A miRNA-mimic based therapeutic particle is disclosed herein. The particles comprise a synthetic miRNA or mimic of miR-187-3p encapsulated in a lipid nanoparticle (LNP) carrier or synthetic miR-193b-5p inhibitor encapsulated in a lipid carrier or their combination encapsulated in a lipid carrier. The lipid nanoparticle carrier is made up of at least four (4) types of lipids, in which the four (4) types of lipids include a) an ionizable cationic lipid selected to be positively charged in a formulation buffer (pH 4), which binds and protects the negatively charged miRNA, and facilitates endosomal escape, and is neutral in a storage buffer, b) a sterol in the structure of the lipid nanoparticle (LNP)., c) a structural helper lipid selected to contribute to lipid nanoparticle stability and/or enhances endosomal release, and d) a PEGylated-lipid selected such that it stabilizes the therapeutic particle and protects it from opsonization.
Absstract of: CN121265558A
本发明提供一种富含大蒜素的植物囊泡及其制备方法和应用，在制备大蒜汁液和连续离心除杂后，采用PEG800富集大蒜素，依次从大蒜中粗提小纳米囊泡，较大的微囊泡，大蒜素聚体和提取亲脂成分，再经过薄膜蒸发成薄膜和水化形成重构囊泡，使得大蒜素能够稳定而丰富地包裹在重组囊泡中，形成ASL‑EVLPs，能够有效包载高含量大蒜素，显著提高大蒜素的稳定性并降低其刺激性。采用本发明的方法制备的富含大蒜素的植物囊泡，采用以药制药的方式，延缓细菌耐药和有效抗感染，可以实现广谱抗菌并延缓细菌耐药，对部分革兰氏阳性菌、阴性菌及真菌均有抑制作用，可用于制备与抗菌有关的药物中。
Absstract of: CN120241626A
According to the preparation method of the LNP freeze-dried preparation, the particle size difference before and after LNP freeze-drying can be reduced and the product quality can be improved by adding salt into an LNP solution, adjusting the pH value or carrying out curing treatment and the like.
Absstract of: CN121265554A
本发明属于肿瘤免疫治疗技术领域，具体涉及一种响应型自组装前药纳米粒子及其制备方法和应用，包括喜树碱衍生物CPT‑C、GSH响应型NO前药SIN‑C，联合mPEG2000‑DSPE构建自组装前药纳米粒子SIN/CPT@NPs，制备方法包括将mPEG2000‑DSPE及前药CPT‑C、SIN‑C溶于氯仿，在旋转蒸发仪中形成均匀脂质薄膜，随后加入超纯水进行水化，超声处理获得纳米混悬液，通过离心分离去除未包封药物及大颗粒，收集上清液即得SIN/CPT@NPs，本发明通过肿瘤微环境GSH特异性触发药物释放，同步诱导DNA损伤、STING通路激活及ICD效应，驱动DC成熟与CD8+T细胞浸润，形成化疗‑免疫协同抗肿瘤闭环。
Absstract of: CN121265553A
本发明公开了叶酸修饰的NK细胞来源的外泌体包载溶瘤呼肠孤病毒复合物及其制备方法和应用。所述复合物中叶酸与NKexo磷脂双分子层通过自组装插入的方式修饰NKexo；所述复合物中通过挤压法将Reo装载到NKexo中。所述方法包括步骤：提取NKexo，叶酸修饰NKexo，和叶酸修饰的NKexo包载Reo。本发明的叶酸修饰的NKexo包载Reo即能依靠NKexo自身的抗肿瘤特性能成为较好的运送载体，又能够通过叶酸与肿瘤中高表达的叶酸受体结合，从而保护并递送更多的Reo到达肿瘤部位，协同联合靶向治疗癌症。
Absstract of: AU2023392764A1
There is provided a pharmaceutical formulation that is useful in the treatment of metabolic disorders or conditions, comprising a plurality of particles suspended in a carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 µm; and (b) comprise solid cores comprising at least one glucagon-like peptide-1 receptor agonist, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is at least about 1:10 and up to and including about 10:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of glucagon-like peptide-1 receptor agonists to treat metabolic disorders or conditions, such as type 2 diabetes and/or obesity without a burst effect. The glucagon-like peptide-1 receptor agonist is preferably liraglutide.
Absstract of: CN120390635A
The present invention provides a lyophilized nucleic acid lipid nanoparticle (NALNP) comprising (a) a lipid nanoparticle comprising a nucleic acid, and (b) a lyophilization buffer comprising a sugar, a lyophilization reagent, and a pharmaceutically acceptable diluent; and a preparation method thereof.
Absstract of: TW202430642A
The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and/or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.
Absstract of: CN120583941A
Provided herein are compositions, systems, kits and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) with a composition i) comprising a plurality of nanoparticles self-assembled by a plurality of fusion proteins comprising a) at least a portion of a ferritin and b) an immunogenic protein, in some embodiments, the fusion protein comprises i) an immunogenic protein comprising at least a portion of an SFTS virus Gn and/or Gc envelope glycoprotein, or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).
Absstract of: AU2023394992A1
The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.
Absstract of: AU2024252577A1
Disclosed herein is a polysialic acid (PSA)-polymer conjugate compound represented by the structural formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200, nanoparticles comprising same, and methods of treating ophthalmic diseases using same.
Absstract of: WO2026004828A1
The present invention addresses the problem of providing a method for producing lipid nanoparticles, the method making it possible to produce lipid nanoparticles having a narrow particle size distribution. The present invention provides a method for producing lipid nanoparticles, the method comprising a step 1 for preparing a first solution containing an active ingredient, a step 2 for preparing a second solution containing a prescribed lipid and an alcohol, a step 3 for mixing the first solution and the second solution in a flow channel to prepare a lipid nanoparticle dispersion, a step 4 for mixing and diluting the lipid nanoparticle dispersion A with a third solution at a given ratio and thereby preparing a lipid nanoparticle dispersion B, and a step 5 including a pH adjustment step for adjusting the pH of the lipid nanoparticle dispersion B and an alcohol removal step, the interval from step 3 to step 4 being less than 1 minute, and the alcohol content of the lipid nanoparticle dispersion B being 6-30 vol%.
Absstract of: WO2026004829A1
The present invention addresses the problem of providing a method for producing lipid nanoparticles, which enables the production of lipid nanoparticles having a narrow particle size distribution. According to the present invention, there is provided a method for producing lipid nanoparticles, the method comprising a step 1 for preparing a first solution that is an acidic aqueous solution containing an active ingredient, a step 2 for preparing a second solution that is a solution containing a specific lipid and an alcohol; a step 3 for preparing a lipid nanoparticle dispersion by mixing the first solution with the second solution in a flow channel, a pH adjustment step for adjusting the pH of the lipid nanoparticle dispersion, and an alcohol removal step, wherein the alcohol content in the lipid nanoparticle dispersion obtained in step 3 is 12.5-33 vol%, and the lipid nanoparticle dispersion is held for 1 minute or more after the completion of the step 3.
Absstract of: WO2026003875A1
The present disclosure discloses a messenger ribonucleic acid (mRNA) molecule encoding for a cystic fibrosis transmembrane conductance regulator (CFTR) protein. The mRNA molecule is encoded by SEQ ID No. 25 or a sequence having 95% identity to SEQ ID No. 25.
Absstract of: WO2026003586A2
The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a herpesvirus. The multisubunit nucleic acid encodes a multisubunit peptide.
Absstract of: WO2026003577A1
The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a hepacivirus. The multisubunit nucleic acid encodes a multisubunit peptide.
Absstract of: WO2026003578A1
The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a respiratory syncytial virus, a metapneumovirus, a human parainfluenza virus, or a combination thereof. The multisubunit nucleic acid encodes a multisubunit peptide.
Absstract of: WO2026003579A1
The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of self-assembling immunogenic sequences or a plurality of self-assembling immunogenic sequences each further comprising one or more target sequence, or a combination thereof, wherein each self-assembling immunogenic sequence of the plurality is connected to an adjacent self-assembling immunogenic sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises one or more signal sequence upstream of one or more of the self-assembling immunogenic sequences of the plurality. Also disclosed are multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein some or all polynucleotide sequences of the plurality comprises a plurality of self-assembling immunogenic sequence, or a plurality of self-assembling immunogenic sequence each further comprising one or more target sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by one or more cleavage sequence and wherein the multisubunit nucleic acid further comprises one or more signal sequence upstream of one or more of the polynucleotide sequence of the plurality. The multisubunit nucleic acid encodes multisubunit peptide.
Absstract of: WO2026002273A1
Disclosed are a nitrogen-containing chain compound, a preparation method, a composition including same, and an application. Specifically, provided are a nitrogen-containing chain compound as shown in formula (I), or a pharmaceutically acceptable salt thereof. An LNP preparation prepared by using the nitrogen-containing chain compound has a relatively uniform nanoparticle size, a high encapsulation efficiency, and high in vivo expression activity.
Absstract of: WO2026000480A1
A nano-formulation for clearing senescent cells, a preparation method therefor, and use thereof. A gingerenone A-loaded aminated dendritic mesoporous silica nano-formulation is constructed. Dendritic mesoporous silica having a unique central radial pore structure is selected as a drug carrier; the drug carrier is further modified with amino groups, and gingerenone A is loaded onto the aminated dendritic mesoporous silica via non-covalent interactions. The obtained nano-formulation has a uniform particle size, and exhibits the characteristics of high drug loading, high encapsulation efficiency, high biocompatibility, rapid cellular uptake, and low cytotoxicity. Moreover, the nano-formulation can significantly enhance the ability of gingerenone A to clear senescent cells, thereby improving the bioavailability of gingerenone A, and broadening the clinical application of gingerenone A. The nano-formulation has good application prospects in functional foods, pharmaceuticals, and cosmetics.
Absstract of: WO2026000083A1
Provided herein are novel sulfur-containing lipids having a structure of Formula (A) or a salt thereof. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.
Absstract of: WO2026000082A1
Embodiments described herein are directed to lipids having a structure of Formula (A) or a salt thereof and wherein A is carbon or nitrogen and the head group comprises a moiety of Formula (B). A1 and A2 are, independently, O or S and G1, G2 and G3 are as defined herein. The lipids may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.
Absstract of: WO2026000081A1
Embodiments disclosed herein relate to sulfur-containing lipids. Examples of lipids described herein have a structure of Formula (A) or a pharmaceutically acceptable salt thereof. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.
Absstract of: CN121243112A
本发明属于生物制药技术领域，具体涉及一种包载异鼠李素的肉苁蓉来源外泌体及制备方法和应用。本发明提供了一种负载异鼠李素的肉苁蓉外泌体（ISO@CD），以强化对氧化应激与线粒体功能的调控，协同增强DMED治疗效果。
Absstract of: CN121243110A
本发明属于药物递送系统构建领域，具体涉及一种“靶‑药”自适转变交联自组装纳米平台及其制备方法和应用。本发明创造性的将阿霉素作为自身口服递送的载体和靶向配体，实现了肿瘤部位的特异性靶向和治疗作用。通过特定的交联材料以二硫键交联将盐酸阿霉素稳定自组装，并使其亲水端糖环锚定在纳米粒表面，通过识别肠上皮细胞顶侧膜上高表达的SGLT1、OCTN2和基底侧的GLUT2，脑微血管内皮细胞和胶质瘤细胞表面的GLUT1从而跨越肠上皮细胞屏障和血脑屏障。该纳米粒不仅显著提高了阿霉素的口服生物利用度，且在脑部有高效的蓄积作用，进一步在高GSH环境下，断裂二硫键，释放阿霉素，实现了安全高效的抗肿瘤作用。
Absstract of: CN121243375A
本发明属于生物医药技术领域，具体公开了一种基于基因工程化细菌外膜囊泡‑脂质体融合的超声响应性纳米颗粒及其制备方法和应用。本发明提供的纳米颗粒OL@Ce6可通过三重协同机制突破肿瘤免疫治疗瓶颈：(1)免疫靶向强化：融合外壳中OMVs富含的PAMPs可被肿瘤微环境中抗原呈递细胞高效识别，显著提升肿瘤抗原递呈效率；(2)智能免疫调控：内核缓释的GM‑CSF强力募集DCs至肿瘤微环境并促进其成熟，建立持续性免疫应答枢纽；(3)声动力‑免疫协同：脂质双分子层中嵌入的声敏剂在超声辐照下爆发ROS，精准诱导肿瘤细胞ICD并释放DAMPs，激活细胞毒性T淋巴细胞深度浸润，形成抗肿瘤免疫正反馈循环。
Absstract of: CN121243380A
本发明公开一种钴酸钙压电声敏剂的制备方法及其在肿瘤治疗中的应用。以硝酸钙、硝酸钴为原料，溶于柠檬酸水溶液并加2%PEG形成前驱液，经80℃水解缩合得溶胶、陈化得凝胶，120℃干燥12小时后800℃煅烧2小时制钴酸钙纳米颗粒，再经PVP表面修饰得钴酸钙压电声敏剂。该声敏剂生物相容性与稳定性良好，具优异压电响应，超声下可形成内置电场，促进电子‑空穴对的分离并抑制其快速复合，提高活性氧产率，可用于肿瘤声动力治疗。其制备装置简易、操作简单、周期快，利于量产，为肿瘤声动力治疗提供新型高效纳米材料平台。
Absstract of: CN121243410A
本发明公开了一种普鲁士蓝肉桂醛纳米酶复合物及其制备方法和应用，属于生物医药技术领域。该复合物由普鲁士蓝纳米颗粒通过共价键或物理吸附负载肉桂醛构成，具有pH响应释放特性、良好的稳定性及协同抗炎抗氧化活性。其制备方法简单、条件温和、易于规模化。实验表明，该复合物能显著改善溃疡性结肠炎小鼠的疾病症状，降低炎症因子水平，增强抗氧化能力，效果优于单一成分，具有良好的临床应用前景。
Absstract of: CN121243374A
本发明公开了一种荧光示踪的靶向光热抗肿瘤纳米颗粒的制备方法，包括如下步骤：步骤1、制备含铁钛酸钡纳米颗粒BaTiO3/Fe；步骤2、用聚乙烯亚胺包裹BaTiO3/Fe，得到含铁钛酸钡纳米颗粒BaTiO3/Fe‑PEI；步骤3、将叶酸、N‑羟基琥珀酰亚胺和二氯乙烷溶解于超纯水中，磁力搅拌，使用NaOH溶液调节pH值至10，得到混合溶液A，将BaTiO3/Fe‑PEI分散于混合溶液A，搅拌反应24h，得到反应液B，透析，离心分离出固体产物，洗涤，得到肿瘤靶向纳米颗粒BaTiO3/Fe‑PEI‑FA；步骤4、将BaTiO3/Fe‑PEI‑FA分散于含有吲哚菁绿的磷酸盐缓冲液，避光反应12h，离心分离出固体产物，洗涤，冷冻干燥，得到荧光示踪的靶向光热抗肿瘤纳米颗粒BaTiO3/Fe‑PEI‑FA/ICG，具有良好的肿瘤靶向性和成像可视性，能够在超声和磁共振双模式成像引导下协同治疗肿瘤。
Absstract of: CN121243358A
本发明提供了一种百日咳mRNA疫苗，所述百日咳mRNA疫苗包含一个或多个mRNA分子，所述mRNA分子编码的抗原包括：百日咳毒素，丝状血凝素；以及，百日咳黏附素。在一些情况中，所述mRNA分子编码的抗原还包括菌毛蛋白2和菌毛蛋白3。本发明通过gC180‑mRNA和FHA456‑mRNA疫苗为基础，配伍增加PRN‑mRNA的三组分百日咳mRNA疫苗，或配伍增加PRN和Fim2/3的五组分百日咳mRNA疫苗提高了百日咳mRNA疫苗的保护效果。
Absstract of: CN121243128A
本发明公开了一种用于治疗肺纤维化的纳米制剂及其制备方法，属于生物医药技术领域。该纳米制剂为双纳米粒制剂，包括靶向远端气道上皮细胞的纳米粒A和靶向肌成纤维细胞的纳米粒B；所述纳米粒A由PLGA‑PEG、PLGA‑PEG‑HA和notch抑制剂制成；所述纳米粒B由PLGA‑PEG、PLGA‑PEG‑Mal、靶向肌成纤维细胞的肽和Hedgehog抑制剂制成。本发明的纳米制剂通过双纳米粒共同调控气道祖细胞向肺泡谱系分化，从而实现肺纤维化的治疗。
Absstract of: CN121243113A
本发明公开了一种脐血间充质干细胞来源外泌体的纳米胶囊化方法，具体涉及生物药品制造技术领域。首先从脐带血中分离、培养间充质干细胞并收集其分泌的外泌体；随后将外泌体悬浮液与特定分子量及脱乙酰度的壳聚糖溶液混合，再按比例加入海藻酸钠溶液，通过静电相互作用初步形成纳米胶囊；最后引入钙离子进行离子交联固化，经洗涤收集后得到稳定的纳米胶囊产品。本发明采用壳聚糖与海藻酸钠天然多糖复合体系，在温和的水相环境中通过简单的混合、滴加、交联三步核心工艺完成封装。本发明不仅工艺流程简便、重现性好、易于标准化规模化生产，而且能有效保护外泌体的天然生物活性与结构完整性。
Absstract of: CN121248636A
本发明公开了一种基于NIR‑II影像的多肽自组装纳米诊疗制剂及其制备方法，是制备一种全新的基于硒代二唑结构的聚集诱导发射发光体TPA‑Se，以其作为荧光探针，结合线粒体靶向前药LND‑1‑PEG‑24，包覆免疫细胞膜构建的影像导航‑免疫治疗‑肿瘤微环境重塑协同纳米体系。本发明不仅实现了制剂的肿瘤部位特异性靶向富集和精确生物成像，还能在肿瘤区域实现化疗药物靶向释放加速肿瘤细胞焦亡，同步实现光热治疗物理杀伤效应和化学治疗生物杀伤效应，为实现精确成像引导的显著杀伤肿瘤细胞及促进肿瘤细胞焦亡提供了新的方案。
Absstract of: CN121243384A
本发明属于生物医药技术领域，提供了PRMT6的新用途，具体是其抑制剂PRMT6抑制剂在制备预防或治疗治疗脓毒症‑ARDS药物中的应用。本发明首次公开了PRMT6作为脓毒症‑ARDS治疗靶点的应用价值。通过靶向抑制PRMT6的表达，可有效抑制肺泡上皮细胞（AECs）内的铁死亡，进而改善了ARDS相关的组织病理学，从而有效改善疾病进展，为脓毒症‑ARDS的靶向治疗开辟了新路径。
Absstract of: CN121243406A
本发明属于药物递送技术领域，具体公开了药物载体、纳米载药颗粒及制备方法和应用。本发明利用天然多酚驱动的多种分子间相互作用，制备的药物载体具有良好的稳定性、生物安全性、生物活性和引人注目的扩展载药谱，可以负载疏水性和亲水性药物。与单纯的人血清白蛋白相比，本发明的药物载体负载效率最高提高96%，实现载体的高载药量和载药普适性。
Absstract of: CN121243214A
本发明公开了改性多糖的水微球在促进伤口皮肤再生和抑制伤口皮肤纤维化中的应用。本发明中，通过与作为对照的Control组（硅油）和未改性的多糖的水微球组（AVBEC）相比，改性多糖的水微球组（AVBER）外用于深Ⅱ级烫伤模型巴马小型猪皮肤时，能够有效促进创面愈合，控制炎症程度和持续时间，调节细胞外基质组成和可塑性，降低纤维化标志蛋白的表达，达到促进皮肤再生和抑制纤维化的双重效果。解决了天然提取物和普通多糖微球产品生物活性低和稳定性差问题，发现改性后多糖的新功能。
Absstract of: CN121243315A
本发明公开了一种用于治疗阴经癌的中药复方靶向纳米制剂及制备方法，该制剂由金银花、土茯苓、当归、黄芪、茯苓、牡丹皮、砂仁、半枝莲、白花蛇舌草、全蝎、水蛭和甘草等原料药经超临界CO2萃取与水提醇沉精制后，与磷脂、胆固醇、表面活性剂构成的纳米载体及叶酸‑PEG‑DSPE靶向配体结合制成。其制备方法包括中药有效部位群的提取、纳米脂质体的薄膜超声法制备、靶向修饰及冷冻干燥。本制剂通过叶酸受体介导的主动靶向作用，使药物特异性富集于肿瘤组织，具备粒径均一、包封率高、pH响应释放及生物利用度高等特点。动物实验证实，显著优于传统汤剂，且安全性良好，为阴经癌治疗提供了高效低毒的新型中药纳米药物。
Absstract of: CN121242138A
本发明提供了一种缓解仔猪肠道氧化损伤的功能性饲料添加剂及其制备方法和应用，所述功能性饲料添加剂以重量份数计包括植物提取物30‑50份、水翁花多酚‑介孔二氧化硅纳米颗粒0.5‑2份、牡荆苷0.05‑1份和甘蔗多酚1‑3份。本发明提供的产品可缓解仔猪氧化应激造成的肠道结构损伤，保护肠道正常结构与功能；降低炎症因子，改善炎症反应，维护肠道健康；减少仔猪腹泻，提高仔猪的生产性能。
Absstract of: CN121248630A
本发明公开了一种近红外二区聚集诱导发光纳米粒子实现的协同光动力‑光热肿瘤治疗，属于使用聚集诱导发光材料用于癌症治疗领域。本发明的近红外二区聚集诱导发光的光敏化合物的制备方法包括以下步骤：将化合物1、化合物2、四三苯基膦钯、碳酸钾在四氢呋喃和水的混合溶液中混合，回流反应，得到化合物3；将化合物3和R2在乙酸酐中混合，反应，得到所述近红外二区聚集诱导发光的光敏化合物。本发明通过分子设计，成功制备了一种集NIR‑II激发、高效I型PDT、超高效率PTT及AIE特性于一体的多功能光敏剂，为解决肿瘤治疗中的缺氧瓶颈和实现高效协同治疗提供了一种全新技术方案。
Absstract of: CN121243111A
本发明公开了一种向巨噬细胞高效递送核酸的脂质纳米颗粒复合物。该复合包括40~70% 可电离阳离子脂质、5~15% 辅助脂质、18~50% 胆固醇和1~2% PEG化脂质。该脂质纳米颗粒复合物采用微流控设备进行制备，制备的脂质纳米颗粒复合物粒径在50~200nnm范围内，PDI小于0.3，粒度分布均一，能够将核酸药物高效递送至巨噬细胞内。
Absstract of: CN121242222A
本发明提供了一种姜黄素‑小米醇溶蛋白‑透明质酸纳米颗粒及其制备方法。具体包括以下几个步骤：（1）负载姜黄素的小米醇溶蛋白‑透明质酸纳米颗粒的制备；（2）透明质酸提高纳米颗粒的包封率。本发明制备的纳米颗粒通过反溶剂沉淀法制备得到，所获的纳米颗粒粒径小且分布均一，稳定性较好，包封率和载药量高。制备体系均为天然来源物质，工艺简单，可以实现小米醇溶蛋白‑透明质酸纳米颗粒的宏量制备，提高疏水性物质的生物利用率，对小米醇溶蛋白的应用具有重要意义。
Absstract of: CN121243285A
本发明提供一种女性更年期调理用精油组合物及其制备工艺，属于调理更年期精油技术领域；其制备方法包括：制备黑升麻提取物纳米复合物；制备复合精油微胶囊；制备精油组合物。本发明通过将乳清分离蛋白和羧甲基淀粉钠分别溶解后，再加热搅拌混合，使二者通过静电吸引初步结合，再加入复配精油，经均质和超声波处理制成复合乳液后，能够显著增加微胶囊的比表面积，提供更多吸附位点，然后通过转谷氨酰胺酶催化乳清分离蛋白分子间谷氨酰胺与赖氨酸的交联反应，形成三维网络骨架，同时羧甲基淀粉钠的羧基可通过离子键与乳清分离蛋白的氨基结合，填充网络间隙，从而能够有效提升对复配精油的包埋率。
Absstract of: CN121243366A
本发明涉及生物药品制造领域，具体为一种具有疫苗免疫增强作用的蒲公英多糖PLGA纳米颗粒的制备方法，所述蒲公英多糖PLGA纳米颗粒的平均粒度为80‑120 nm，Zeta电势为‑35.5±0.5mV，包封率≥84%，24 h释放率≥83%。本方案制得了包封率≥84%，载药量≥4.5%，24 h释放率≥83%且能够稳定储存的蒲公英多糖PLGA纳米颗粒，能够应用于疫苗药物，具有疫苗免疫增强作用。
Absstract of: CN121243255A
本发明提供了一种预防白内障、黄斑病变和糖网病变的组合物以及制备方法和应用，属于生物医药技术领域。本发明组合物，包括：纳米活性成分、植萃提取物、甘草酸二钾、烟酰胺、牛磺酸、依克多因、咖啡因和叶黄素；植萃提取物由野菊花提取物和龙胆提取物组成；纳米活性成分由纳米包裹虾青素和纳米视黄醇组成。本发明组合物通过抗氧化‑抗炎‑血管保护‑代谢调节的多维协同机制，有效抑制晶状体蛋白氧化变性、视网膜色素上皮细胞功能衰退及病理性血管生成等关键病理环节，从而实现对白内障、年龄相关性黄斑变性与糖尿病视网膜病变三种主要致盲眼病的预防与辅助治疗作用。
Absstract of: CN121249652A
本发明公开了一种三螺旋结构元件在RNA药物设计中的应用，属于生物医药领域。所述应用为：将ENE元件或其突变体作为核酸稳定元件，通过优化3’UTR与poly(A)的相互作用，增强mRNA稳定性并进一步提升蛋白翻译效率，从而有效解决RNA疗法中蛋白表达量低的问题。本发明提出的mRNA序列优化策略为传染病及肿瘤免疫治疗领域的疫苗设计提供了新方法，具有广泛的应用前景。
Absstract of: AU2024279267A1
Disclosed is a pharmaceutical composition for inhalation, comprising lipid carriers comprising a pharmaceutical agent, the therapeutic uses thereof, and a method of making same.
Absstract of: AU2023407128A1
Provided herein is an ionizable, cationic amino lipid or a pharmaceutically acceptable salt thereof. The ionizable, cationic amino lipid has: a protonatable amino head group; two lipophilic chains, wherein the protonatable amino head group has a central carbon atom to which each of the two lipophilic chains are directly bonded; at least one of the two lipophilic chains has a structure of Formula C: Formula C wherein E is an ester in either orientation. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.
Absstract of: WO2024253582A1
There is provided a nanoparticle composition comprising a compound represented by general formula (1) or ionized form thereof, wherein R1, R2, and R4 to R8 are each independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, R3 is optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene, and R9 and R10 are each independently a hydrophobic tail or contains at least one of the groups defined above for R4 to R8; a therapeutic, prophylactic, and/or biological agent that is encapsulated by the compound of general formula (1) to form nanoparticles; and a cryoprotectant. There is also provided a method of preparing said nanoparticle composition.
Absstract of: CN121248455A
本发明提供一种基于N‑乙酰半胱氨酸的可电离脂质、脂质纳米粒及制备方法与应用。本发明所提供的全新结构的可电离脂质，其可形成粒径均一、结构稳定的LNP，转染效率高且生物相容性好。此外，所制备的LNP具有低免疫原性，能够引起免疫细胞(如巨噬细胞、树突状细胞)较低共刺激分子的表达。
Absstract of: TW202438045A
The present disclosure relates to a lipid compound of formula (AL-GI):, having various cleavable linkers defined by the variables Z1 and Z2. The present disclosure also relates to a lipid carrier or lipid nanoformulation employing the lipid compound, and the use of the lipid compound in a pharmaceutical composition as well as for a method of delivering a therapeutic agent.
Absstract of: WO2026003582A2
The disclosure provides for lipids that may be formulated in a delivery vehicle to facilitate the encapsulation of a wide range of single or multiple payloads including therapeutic, theragnostic, preventive, prophylactic, pre-emptive, and diagnostic agents, such as, without limitation, nucleic acids (e.g., RNA or DNA), proteins, peptides, and small molecule active pharmaceutical ingredients (APIs). Methods of delivering and/or producing a polypeptide of interest in a cell are also provided.
Absstract of: WO2026006634A1
The present disclosure provides, inter alia, compositions of LNPs that are suitable for nebulization, and associated methods of making and using the same. In certain aspects, the present disclosure provides LNPs, and compositions comprising them, comprising a simple block stabilizer, to form a LNP composition that is suitable for delivery of a nucleic acid therapeutic to a subject by nebulization, where the LNP remains stable post-nebulization. These compositions can be used to treat a variety of diseases and disorders by delivering a wide array of therapeutics, such as nucleic acid therapeutics, including nucleic acids encoding a protein sequence.
Absstract of: WO2026006196A1
A compound having the structure (I) is provided. The compound is useful as a therapeutic agent in the form of a lipoplex, or in a form of a polyplex, in a form of a lipid nanoparticle, or in a form of a liposome, or in a form of a micelle, or in a form of an emulsion including a drug, vaccine, oligonucleotide, antibody, enzyme, protein, small molecule, or nucleotide.
Absstract of: WO2026006790A2
Provided herein are nanoparticles comprising a triblock copolymer and a targeting moiety for targeted delivery of one or more therapeutic agents, and formulations thereof. Also provided herein are layered drug delivery vehicles. Further provided herein are methods, or uses thereof, for treating cancers, preferably pancreatic and brain cancers, by administration of the nanoparticles disclosed herein.
Absstract of: WO2026006759A1
Pharmaceutical compositions of Compound (I) including solid dispersions of Compound (I) and nanocrystalline powder forms of Compound (I). Related unit dosage forms, and methods of making and using the same are also provided.
Absstract of: WO2026006579A1
Compounds are provided having the following structure: (I), or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein Y, Q, R, Ri, R2, m, n and o are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided. Formula (I).
Absstract of: WO2026006618A1
Spherical nucleic acids (SNAs) are an attractive platform for therapeutic delivery due to their chemically tunable structures, biocompatibility, and ability to rapidly enter cells without transfection reagents. The present disclosure provides SNAs and strategies for delivering genome editor proteins into cells. Concurrent delivery of genome editor proteins and a single-guide RNA in an SNA platform allows for rapid entry into mammalian cells and effective genome modification.
Absstract of: WO2026006555A1
The invention relates to a method for producing lipid nanoparticles (LNPs), comprising the steps of (a) performing a reference method for the preparation of LNPs, the reference method comprising the steps of (a1) introducing a first inlet stream of an aqueous solution via a first inlet port of a first mixing chamber, and introducing a second inlet stream of a lipid solution via a second inlet port of the first mixing chamber, thereby mixing the aqueous solution and the lipid solution so as to produce LNPs, and (a2) recovering a first outlet stream comprising the produced LNPs via an outlet port of the first mixing chamber, and (b) producing LNPs according to the reference method in a second mixing chamber, wherein the inner diameters of the first inlet port, second inlet port and outlet port of the second mixing chamber are each by the same factor proportionally bigger by at least 5% than the inner diameters of the first inlet port, second inlet port and outlet port of the first mixing chamber, wherein the linear flow rate of the first outlet stream and the second outlet stream are essentially identical.
Absstract of: WO2026006524A2
The present invention provides, in part, cationic lipid compounds of Formulae (I), (II), (III), (IV), (V), or (VI) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Absstract of: WO2026006617A1
The present invention relates to lyophilized and frozen pharmaceutical formulations comprising a nucleic acid (NA)-lipid nanoparticle (LNP) particle, wherein the NA-LNP particle comprises a nucleic acid encapsulated in the lipid nanoparticle, wherein the formulation further comprises an excipient comprising a lyoprotectant or cryoprotectant and a buffer, and wherein the lyoprotectant or cryoprotectant is a polyvinylpyrrolidone (PVP) or a polyethylene glycol (PEG). Methods of making the lyophilized and frozen formulations are also provided.
Absstract of: WO2026003770A1
A formulation for nutraceutical and/or pharmaceutical use based on protein nanoparticles is described, including a bioactive compound chosen from hydroxytyrosol, tyrosol, olive phenolic compounds, and mixtures thereof, and a zein protein matrix stabilized with sodium deoxycholate.
Absstract of: WO2026006513A2
Alcohol dehydrogenase 1 enzymes, aldehyde dehydrogenase 2 enzymes, nucleic acids encoding alcohol dehydrogenase 1 enzymes and aldehyde dehydrogenase 2 enzymes, lipid nanoparticles, lipid nanoparticles comprising nucleic acids encapsulated therein, pharmaceutical compositions comprising lipid nanoparticles which comprise nucleic acids encapsulated therein are useful for treating alcohol-related conditions, such as alcohol poisoning.
Absstract of: WO2026006393A1
Disclosed are compounds, nanoparticles, and compositions for effective delivery of metabolic inhibitors to disease state cells. Also disclosed are methods of treating a subject in need thereof, such as a subject with cancer.
Absstract of: WO2026006769A1
The present invention provides a fungal drug carrier comprising an avirulent fungal pathogen cell, for example a Cryptococcus neoformans cell, linked to one or more surface-bound drug-loaded nanoparticles, and methods of making the fungal drug carrier. The invention provides methods of using the fungal drug carrier to deliver a drug to the central nervous system of a patient, wherein the fungal drug carrier is phagocytosed by an immune cell of a patient, transported across the blood-brain barrier, and vomocytosed to allow drug release from the surface-bound nanoparticle into the central nervous system of the patient. The methods involve treating a central nervous system in a patient comprising administering to the patient a pharmaceutical composition comprising a fungal drug carrier.
Absstract of: WO2026006565A1
A method of introducing a polynucleotide into wheat seed using nanoparticles, e.g., mesoporous silica nanoparticles or silica nanoparticles comprising a polynucleotide, e.g., a polynucleotide for use in gene editing, transgene insertion, upregulation of gene expression, or downregulation of gene expression.
Absstract of: WO2026006281A1
Provided herein is a system for delivering genetical material, preferably subcutaneously, and its various elements. Also provided are related compositions and methods.
Absstract of: WO2026006092A1
Provided herein are compositions, systems, kits, and methods for treating a patient with a disease or condition by administering nanoparticles comprising a biocompatible polymer, wherein the nanoparticles fully, or almost fully, encapsulate: i) tissue-type plasminogen activator (tPA), ii) at least one antioxidant enzyme selected from: superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase, and optionally iii) plasmin protein. In certain embodiments, the disease or condition is selected from: thromboembolism, ischemia-reperfusion injury, stroke, spinal cord injury (SCI), Alzheimer's disease, Muscular Dystrophy, Hypercoagulability, Vaso-occlusive conditions, a fibrotic condition, internal tissue scarring, peritoneal scarring, wound associated scarring, surgical incision associated scarring, and/or dermal scarring.
Absstract of: WO2026002313A1
A system and method are disclosed for the production of drug delivery vesicles formed from hydroxyapatite (Ca10(PO4)6(OH)2), called apasomes, using a microfluidic device. The device comprises a first inlet with a bifurcated tube and a second inlet with an inlet tube. Hydroxyapatite nanoparticles and, optionally, therapeutic agents suspended in a second fluid are introduced into the device via the second inlet, while a miscible first fluid is introduced via the first inlet. The two fluids are combined at a mixing point within the device and the combination fluid travels through an elongate tube before exiting the device. Shear forces cause self-assembly of vesicles, the size of which can be modified by adjusting the flow rates, the shapes and dimensions of the tube, and the composition of the fluids. The method may also include refluxing, filtration and drying steps to enable scalable production of customizable drug delivery vesicles for therapeutic applications.
Absstract of: WO2026003403A1
It is provided a novel lipid of formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer of any one of them, and a nanoparticle comprising the ionizable lipid, particularly as encapsulating agent, optionally comprising a molecule or a pharmaceutically active inside. It is also provided a lipid nanoparticle or a pharmaceutical composition comprising thereof for use in medicine, and the use of the lipid nanoparticles as encapsulating agents. Formula (I)
Absstract of: WO2026005944A1
A compound having the structure (I) is provided. The compound is useful as a therapeutic agent in the form of a lipoplex, or in a form of a polyplex, in a form of a lipid nanoparticle, or in a form of a liposome, or in a form of a micelle, or in a form of an emulsion including a drug, vaccine, oligonucleotide, antibody, enzyme, protein, small molecule, or nucleotide.
Absstract of: WO2026003373A1
The present invention provides lipids of Formula (I) to (IX) or subformulae thereof, or pharmaceutically acceptable salts thereof. Said lipids can be useful for the delivery and expression of mRNA and encoded protein, e.g. as a component of liposomal delivery vehicles, and accordingly can be useful for treating various diseases, disorders, and conditions, such as those associated with deficiency of one or more proteins. Compositions comprising lipid compounds of Formulae (I) to (X) and subformulae thereof, and mRNA encoding a peptide or protein may be administered to subjects in need thereof intranasally.
Absstract of: WO2026005574A1
Provided are transition metal dichalcogenide (TMD)-based antibody mimetic comprising: a transition metal dichalcogenide nanosheet; and a tripeptide bound to the nanosheet. The antibody mimetic according to the present invention can strongly bind to PD-L1 with a dissociation constant at the nanomolar level, and can selectively bind to albumin and immunoglobulin (IgG1), which are major plasma proteins, at least 1.5 times more selectively. As a result, imaging of PD-L1-overexpressing cancer cells is possible by treating PD-L1-overexpressing cancer cells with a TMD nanosheet antibody mimic so as to detect the Raman scattering signal, which is an intrinsic optical characteristic of the material. In addition, the PD-L1/PD-1 binding blocking effect of the TMD nanosheet antibody mimetic, according to the present invention, can be identified at the cell level and the cancer cell transplantation animal model level, and thus the TMD nanosheet antibody mimetic can also function as an immunotherapeutic agent.
Absstract of: WO2026005488A1
The present invention relates to an autoantigen-specific nanofusion vaccine composition for the treatment of systemic sclerosis, the composition being for simultaneous immunomodulation and antifibrosis. A nanofusion body carrying a vimentin peptide according to the present invention was found to inhibit tissue fibrosis in systemic sclerosis, reduce the amount of autoantibodies in serum, and regulate the expression of immune-regulatory cells and pathogenic cells associated with systemic sclerosis. The nanofusion body was also found to inhibit tissue fibrosis and to exhibit enhanced anti-fibrotic effects, when co-administered with a vimentin antibody, in an animal model reflecting the immune status of systemic sclerosis patients. In addition, the nano-vaccine was found to decrease the expression of fibrotic and pathogenic factors in tissues and was also found to improve disease activity not only in vimentin-specific systemic sclerosis but also in infection-associated systemic sclerosis.
Absstract of: WO2026005041A1
The present invention provides a neutron capture therapy agent with a superior therapeutic effect. The present invention provides modified boron carbide nanoparticle powder with a suitable particle diameter for polyglycerol-functionalized boron carbide, capable of producing a boron neutron capture therapy (BNCT) agent that exhibits high accumulation efficiency in tumors and excellent therapeutic efficacy, with the surface of the boron carbide nanoparticles not coated with graphite.
Absstract of: WO2026002534A1
The present invention refers to the use of novel polyoxyalkylene based block copolymers in particles or in medical devices, wherein the particles comprise at least one novel polyoxyalkylene based block copolymer and preferably at least one active agent.
Absstract of: EP4670743A1
The present disclosure relates to an albumin nanocomposite comprising a phytochemical and a composition for muscle disease comprising the same, and more specifically, to an albumin nanocomposite comprising a phytochemical that exhibits an effect of inhibiting muscle loss caused by oxidative stress or inflammatory response and promoting the differentiation of myoblasts into muscle cells. The albumin nanocomposite comprising the phytochemical effectively delivers the phytochemical by targeting immune cells that induce reactive oxygen species and inflammatory responses. Accordingly, by regulating muscle-loss signaling pathways induced by reactive oxygen species and inflammatory responses, the nanocomposite inhibits muscle cell atrophy and promotes differentiation. Therefore, a composition comprising the albumin nanocomposite comprising the phytochemical according to the present disclosure can be provided as a composition for improving, preventing, or treating muscle diseases.
Absstract of: CN120379698A
The invention discloses a preparation method of a biomolecule cross-linked compound. In particular, the method comprises the steps of reacting a plurality of monomers with a plurality of comonomers in the presence of ammonia in a first solution to form a compound; extracting the obtained compound from the first solution for cleaning; reacting the cleaned compound with a second solution, and connecting a crosslinking agent to the compound through a first amine functional group of the crosslinking agent; and adding a plurality of biomolecules into the second solution, and combining the biomolecules with the compound through a second amine functional group of the cross-linking agent to prepare the biomolecule cross-linked compound.
Absstract of: EP4671238A1
The disclosure relates to a novel sulfide-containing ionizable lipid. The ionizable lipid of the disclosure interacts electrostatically with an anionic drug when a lipid nanoparticle is produced, thereby ensuring that the drug is encapsulated in the lipid nanoparticle with high efficiency and the drug is stably delivered into the body, facilitating its utility in the related art such as lipid nanoparticle-mediated gene therapy.
Absstract of: EP4670735A1
A prodrug nanoparticle for targeted accumulation and activation (treatment) in tumor tissue, that consists of a Pt(IV) complex with the following formula:wherein R<sub>1</sub> und R<sub>2</sub> are the same or different branched or unbranched alkyls having at least 14 carbon atoms, a sonosensitizer and a biocompatible drug delivery system can be used to treat tumors and in particular metastases in a way that is well tolerated by the body. The prodrug nanoparticles according to the invention are particularly suitable for the treatment of mammary carcinomas, pancreatic carcinomas, prostate carcinomas, bronchial carcinomas, endometrial carcinomas, germ cell tumors, non-Hodgkin's lymphomas and malignant mesotheliomas and, in particular, colorectal carcinomas, and their respective metastases.
Absstract of: EP4671297A1
The present invention refers to the use of novel polyoxyalkylene based block copolymers in particles or in medical devices, wherein the particles comprise at least one novel polyoxyalkylene based block copolymer and preferably at least one active agent.
Absstract of: AU2025271424A1
Abstract The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use. ov o v
Absstract of: CN120826219A
The present invention relates to polymer nanoparticles having a core-at-shell structure comprising poly (3-hexylthiophene) in the core and poly (3-hexylthiophene)-S, S-dioxide in the shell and having a critical oxidation fraction for use in the amelioration and/or treatment of degenerative retinal diseases.
Absstract of: CN120569204A
The present invention relates to the use of a composition comprising a newly synthesized extracellular matrix for the treatment of cancer, in particular for inhibiting cancer cell viability, migration and proliferation.
Absstract of: AU2025271414A1
22248698_1 (GHMatters) P127259.AU.1 The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use. ov o v
Absstract of: MX2025009878A
<p num="0000"/>
Absstract of: EP4670711A1
This invention relates to liposomes having mucopenetrating action and rates of incorporation of a retinoid, for example retinoic acid (RA), greater than those obtained in solid lipid nanoparticles (0.1%), thus increasing the uptake thereof via the nasal mucosa, and to the method for preparing a liposome. The present invention also relates to an intranasal composition, for example a vaccine, comprising said liposome, which is more effective than existing vaccines, the method for preparing same and the use thereof for preventing illnesses.
Absstract of: WO2024178237A2
This disclosure provides an engineered delivery system, including a bacterial membrane vesicle derived from bacteria and one or more non-bacterial proteins for anchoring to the bacterial membrane vesicle.
Absstract of: EP4670721A2
This invention relates to a composition for ophthalmic delivery of a therapeutic agent, the composition comprising an oil-in-water (o/w) microemulsion comprising a fatty acid, or fatty acid ester, as the oil phase; an aqueous phase; a surfactant; and a co-surfactant, and wherein the composition further comprise a suspension of therapeutic agent-loaded nanoparticles. Use of the composition for the treatment or prevention of an eye disorder, a method of treatment or prevention of an eye disorder and an eye drop dispenser are also provided.
Absstract of: EP4670794A2
This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of T<sub>R</sub>1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.
Absstract of: GB2642161A
This disclosure provides the use of nanoparticles comprised of self-assembling acidic molecular clusters to treat wounds alone or with selected essential and/or antimicrobial ionic metals that can be applied to prevent infections or treat wounds or infected sites of the skin and underlying tissue of mammals.
Absstract of: CN121221794A
本发明涉及内体膜标记纳米粒在靶向降解细胞外蛋白中的应用，属于纳米生物医药技术领域。本发明提供的内体膜标记纳米粒以高分子有机材料为载体，在其表面修饰胞外蛋白靶向肽，以及由内体插膜多肽和吞噬体靶向肽组成的内体锚定吞噬体靶向肽，构建得到的纳米粒可特异性识别细胞外靶蛋白，通过靶蛋白的内吞机制进入细胞内体，其插膜多肽插入内体脂质膜，将末端的吞噬体靶向肽锚定于内体表面，招募细胞质吞噬体进行吞噬，最终利用通过内体‑吞噬体‑溶酶体途径实现对目标蛋白的降解。该内体膜标记纳米粒制备方法简便，兼具良好的生物安全性和高效递送能力，在生物医学研究和临床治疗领域具有巨大的潜力。
Absstract of: CN121226499A
本发明涉及一种多肽及其作为基因递送载体的应用。所述多肽可由下式(I)表示。本申请开发的基于多肽的安全高效的肺部基因递送多肽MNM，实现了高效的siRNA包载，并克服了肺部和细胞屏障，可有效用于肺纤维化的治疗。
Absstract of: WO2024237865A1
This disclosure concerns a hydrogel ink comprising lipid particles, polynucleotides loaded within the lipid particles and a bioink. In one embodiment, the lipid particles comprise extracellular vesicles. The disclosure also concerns the hydrogel thereof, and its use in treating a neural disease or condition, or regenerating a soft tissue.
Absstract of: NZ819515A
The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. The exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety selected from a guanidine group, zwitterion group, a diethylene triamine, or a combination thereof; configured to provide desired properties for the polymersome. Exemplary initiator blocks are shown in the abstract drawing.
Absstract of: CN120682120A
Provided herein are lipid compounds, such as compounds of Formula (I). Also provided are lipid nanoparticles and pharmaceutical compositions, each comprising a lipid compound, such as a compound of Formula (I).
Absstract of: CN121221746A
本发明公开了一种治疗糖尿病导致的勃起功能障碍的制剂及其制备方法和应用。本发明率先发现Fbp1功能区260位点旁边具有棕榈酰化修饰位点，即282位点，该位点能被棕榈酰化位点修饰而导致Fbp1功能受损。因此，本发明首次发现并合成了C282S位点的点突变修饰Fbp1mRNA，即282位点的半胱氨酸转换为丝氨酸，因此Fbp1不会受到Zdhhc13棕榈酰化修饰进而功能受损，并合成了可靶向递送修饰后Fbp1mRNA的脂质纳米颗粒，将此纳米颗粒负载的C282S‑Fbp1mRNA打入小鼠海绵体内，不仅恢复了Fbp1的数量，也防止Fbp1功能受到损害，因此有效降低DMED阴茎海绵体乳酸浓度，显著改善了DMED小鼠勃起功能。
Absstract of: CN121221561A
本发明涉及一种基于转谷氨酰胺酶交联的大米淀粉‑大豆分离蛋白双酚纳米载体及其制备方法，属于功能性食品/医药递送系统技术领域。本发明纳米颗粒的制备方法，包括以下步骤：S1：将糊化淀粉与水化蛋白质充分混合，得到复合载体；S2：将多酚与复合载体充分混合，得到包埋活性物质的复合载体；S3：将转谷氨酰胺酶与包埋活性物质的复合载体混合，酶促交联，得到酶促交联反应物；S4：将酶促交联反应物与醇溶液充分混合，固液分离，得到所述纳米颗粒。本发明包埋率高，复合载体与活性物质的亲和性提升；稳定性强，酶促交联形成的三维网络结构显著提升颗粒稳定性，活性物质保留率高；安全性高，全程采用物理处理与生物酶交联，无化学试剂残留。
Absstract of: CN121221559A
本发明属于药物递送系统技术领域，具体涉及一种共载核酸和化疗药物的LNP递送系统及其应用。所述LNP递送系统以脂质纳米颗粒为载体，所述载体对药物组分进行包封，其能够有效平衡RNA类分子和化疗药物在同一LNP递送系统中的包封率，满足二者给药浓度，不仅节约成本，而且有效避免引入新的免疫原，降低免疫风险。此外，本发明构建了能够同时满足主动靶向性、血液长循环性和低免疫原性的主动靶向型PEG化脂质衍生材料。将其作为上述LNP递送系统的PEG‑脂质得到的主动靶向型共载核酸和化疗药物的LNP递送系统显著提升了RNA类分子的基因敲低效率与化疗药物的抗肿瘤活性，能够有效克服癌症化疗耐药的问题，尤其适用于癌症联合治疗。
Absstract of: WO2024251638A1
The submicron sized particle is substantially spherical, comprising an oily core containing the peptide active and a wax shell that is solid at room temperature The particle is stabilized by an outer layer of a high-HLB non-ionic surfactant. The invention provides a method for obtaining an aqueous suspension of said particles with a satisfactory degree of encapsulation and improved long-term stability, for use in particular in the cosmetics industry. Peptide active associations can be considered, incorporated into the particles and adsorbed on the outside of the particles.
Absstract of: CN121221562A
本发明提供了一种在体外唾液酸‑钙离子自组装纳米颗粒(SA‑CaNPs)的制备方法，涉及有机化学、生物医药纳米、分子生物学等技术领域。所述纳米颗粒由唾液酸衍生物(优选N‑乙酰神经氨酸)与二价钙离子自组装形成，粒径300‑500nm。其制备方法包括：将唾液酸溶液与氯化钙溶液混合，搅拌自组装，无需有机溶剂或表面活性剂。该颗粒中SA能够天然结合肿瘤/脑部高表达的Siglec受体，有望提高药物主动靶向性；Ca2+在溶酶体酸性环境(pH 5.0)下解离，能够响应释放药物。两者自组装形成的纳米颗粒或在载药领域具有广泛应用前景。
Absstract of: WO2025140590A1
The present invention provides a glycine-containing cationic lipid. The structure of the glycine-containing cationic lipid is shown as general formula (1-A), wherein the definition of each symbol is consistent with that in the description. The glycine-branched cationic lipid has a nitrogen-containing heterocycle as a central branched core, has glycine as a secondary branched core, and has a saturated or unsaturated hydrocarbon group as a tail chain, and has the advantages of low toxicity, low immunogenicity, and high biocompatibility. Glycine contained in the novel cationic lipid of the present invention can provide a tertiary amine structure while serving as the secondary branched core, and form a multi-stage tertiary amine structure together with the nitrogen-containing heterocycle central core, increasing the number of tertiary amines capable of being ionized to produce positive charges. When preparing an LNP, the amount of cationic lipid used is less, which is safer and improves the translation efficiency of nucleic acids.
Absstract of: CN121221558A
本发明公开了一种集成递送系统及其制备方法与应用，属于生物医药技术领域。本发明将带正电荷的树枝状大分子和质粒形成复合物纳米颗粒，再经工程化的细菌外膜囊泡包裹构成集成递送系统。该集成递送系统能够解决富含基质类肿瘤存在基质屏障、基因药物难递送、免疫细胞难浸润的问题，且制备简单，具有肿瘤蓄积能力强、生物相容性好等一系列作用，实现了肿瘤组织三个不同细胞靶点的同步治疗，可以对胰腺癌基质中的物理屏障、趋化因子屏障和免疫抑制屏障进行协同攻克，增强CD8+T细胞的杀伤力，增强免疫治疗效果，具有良好的实际应用价值。
Absstract of: CN121221631A
本发明涉及靶向抑制circPDK1试剂在制备抗食管癌药物中的应用，属于生物医药领域。本发明提供了靶向抑制circPDK1表达的试剂为shRNA或siRNA，体内和体外实验证明，其能显著抑制circPDK1的表达，并抑制食管癌肿瘤细胞的生长和迁移；将靶向环状circPDK1的siRNA包装成高效、低毒的LNP‑siRNA后，特异性沉默circPDK1表达，能显著抑制食管癌肿瘤的增殖、迁移，为食管癌相关circRNA的临床治疗和科学研究提供了基础。
Absstract of: CN121221802A
本发明属于生物医药技术领域，涉及一种用于酒精肝损伤治疗的纳米药物。本发明根据酒精性肝损伤时lincRNA‑p21影响自噬和铁死亡两种程序性细胞死亡途径构建纳米药物ferr‑1/lincRNA‑p21@NP，治疗酒精性肝损伤，具有降低损伤的线粒体与脂质积累和降低细胞氧化水平双重功效，可以显著改善酒精性肝损伤。在慢性肝损伤中治疗中，纳米药物可以间隔三天给药一次，使用方便。
Absstract of: CN121221564A
本发明提供了一种GSH触发的光敏剂递送纳米颗粒，它是由红紫素、Cu²⁺、Ce6为原料制备而成，其中红紫素与Cu²⁺的摩尔比为：1:（1‑4）；红紫素与Ce6的摩尔比为1：1。本发明还提供了该纳米颗粒的制备方法。本发明建立了一种新颖的代谢‑免疫协同调控范式，为结直肠癌提供了具有高转化潜力的易适应纳米治疗解决方案。
Absstract of: CN121221762A
本发明公开了一种肿瘤靶向纳米光动力治疗系统及其制备方法：制备多孔NaYF4：Er@NaGdF4持久发光性纳米粒子；制备ES‑PEG‑p(API‑PPA)‑Ce6；将ES‑PEG‑p(API‑PPA)‑Ce6和亲水性药物混合，滴入NaYF4：Er@NaGdF4，诱导PLNPs的包封和胶束形成，加入聚醚F‑127，调节pH值至中性，制得肿瘤靶向纳米光动力治疗系统。本发明提供肿瘤靶向纳米光动力治疗系统具备可逆“开‑关”余辉特性，将精确的手术导航与增强的ROS产生相结合，可联合PDT使用，用于胰腺癌等深部肿瘤的靶向治疗，具有较高的临床应用价值。
Absstract of: CN121221560A
本发明公布了酸性pH响应生物正交交联型AIE纳米体系的构建方法及其应用，包括纳米粒1和纳米粒2，所述纳米粒1由PCL‑PEG、PCL‑PAE‑DBCO和AIE光敏剂组成，所述纳米粒2由PCL‑PEG、PCL‑PAE‑N3和AIE光敏剂组成，本发明的有益效果是，在酸性环境(pH 6.5)下，其PAE的链长大于PEG的链长，以有效地将生物正交基团推到纳米粒外层，触发纳米粒1和纳米粒2之间发生生物正交反应后相互交联在一起，其包载的AIE光敏剂不仅可用于荧光成像，还可产生I型活性氧，有效耐受肿瘤乏氧，实现增强肿瘤光动力治疗的效果。
Absstract of: WO2025209467A1
The present disclosure relates generally to lipids, lipid nanoparticle formulations, and methods of using the same for delivering nucleic acids, such as mRNA.
Absstract of: CN121221563A
本发明公开了一种以柠檬酸盐为模板的蛋白中空粒子制备方法与应用，属于食品技术领域。本发明选用小分子有机盐作为牺牲模板，柠檬酸盐即作为牺牲模板，又作为中空粒子的稳定剂；选用醇溶蛋白为蛋白模型，通过反溶剂沉淀法制备得到单独或者包埋疏水性功能因子的醇溶蛋白中空粒子；柠檬酸盐作为牺牲模板的中性附近温和条件，对姜黄素等疏水性功能因子影响较小的。本发明所述的醇溶蛋白中空粒子制备方法，具有pH中性、低盐、工艺步骤精简和高粒子稳定性和活性成分稳定性等优势，并且能实现对姜黄素等疏水性功能因子的高效包埋。
Absstract of: WO2025264026A1
The present invention relates to: a cerium oxide nanocomposite in which a shell layer comprising a cationic amino acid and PVP is formed on a core layer of cerium oxide nanoparticles; and a composition comprising same as an active ingredient for improving skin conditions. Employing lysine, which is an optimal amino acid capable of functioning as a multifunctional ligand among various amino acids, the nanocomposite of the present invention exhibits both excellent particle properties and maximized reactive oxygen species scavenging activity within skin tissue. Therefore, it can reduce and alleviate various skin tissue damages caused by oxidative stress including skin aging.
Absstract of: KR20250179343A
siRNA, mRNA와 같은 핵산 치료제의 생체 내 안정성을 높이기 위하여 핵산 치료제를 로딩할 수 있는 열 반응성 이온화 역 폴리머와 이를 포함하는 미셀나노입자 및 이를 제조하는 방법에 관한 것이다.
Absstract of: CN121221557A
本发明提供一种骨靶向核酸药物递送系统及其制备方法和应用，其特征在于，所述骨靶向核酸药物递送系统的活性组分包括用于负载核酸的强正电性乳铁蛋白纳米粒、骨靶向分子和核酸药物，所述的负载核酸的强正电性乳铁蛋白纳米粒是在乳铁蛋白纳米粒表面共价修饰可聚合丙烯酰基基团，所述的骨靶向分子为阿仑膦酸，所述的阿仑膦酸表面共价修饰可聚合丙烯酰基基团。所述核酸药物包括具有抑制骨吸收功能的小干扰核糖核酸、微小核糖核酸和核酸适配体中的一种或几种。本发明所述的骨靶向核酸药物递送系统是通过原位自由基聚合的方法来制备。本发明所制备的骨靶向递送系统可以高效地靶向递送至骨组织，有利于调控破骨细胞的功能，并通过调节免疫平衡改善骨炎症微环境，有效促进骨质疏松疾病的骨再生，可广泛应用于骨科疾病的治疗。
Absstract of: CN121221784A
本发明公开了一种含黏液溶解剂的脂质纳米粒冻干保护剂组合物、脂质纳米粒制剂及应用，属于生物医药技术领域，该冻干保护剂组合物包含糖类和黏液溶解剂。本发明首次将糖类与黏液溶解剂组合形成一个冻干保护剂组合物体系。通过糖类与黏液溶解剂的协同作用，使脂质纳米粒经冻干后可在室温下稳定储存，无需冷链，显著降低了储存和运输成本，提升了制剂的临床应用便利性。在体外黏液模型和体内的小鼠哮喘模型中均已证实其可有效提升肺部药物递送效率，增强治疗效果。
Nº publicación: CN121241046A 30/12/2025
Applicant:
解放生物股份有限公司
Absstract of: AU2024279964A1
The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).
BOPI
Electronic site
